
CLYM Stock Forecast & Price Target
CLYM Analyst Ratings
Bulls say
Climb Bio is a clinical-stage biotechnology company with a solid financial foundation and a promising drug pipeline, including their lead drug Uplizna and new drug budoprutug. Despite industry risks, Climb Bio is expected to see positive outcomes in the next 18 months due to their strong financial position and potential in multiple therapeutic areas.
Bears say
Climb Bio is a clinical-stage biotechnology company with a focus on developing therapeutics for immune-mediated diseases. While they have received FDA Fast Track Designation for their lead candidate, Budoprutug, for the treatment of primary membranous nephropathy (pMN), there are currently no approved treatments for this indication in the US alone. The company also faces potential competition from off-label use of anti-CD20 monoclonal antibodies, and the potential for CD19 inhibition to provide deeper B-cell depletion may not be enough to outweigh the risk of unwanted side effects with this novel modality.
This aggregate rating is based on analysts' research of Climb Bio Inc and is not a guaranteed prediction by Public.com or investment advice.
CLYM Analyst Forecast & Price Prediction
Start investing in CLYM
Order type
Buy in
Order amount
Est. shares
0 shares